WO1992005797A1 - Chemico-inmunological antineoplastic preparation - Google Patents
Chemico-inmunological antineoplastic preparation Download PDFInfo
- Publication number
- WO1992005797A1 WO1992005797A1 PCT/JP1990/001300 JP9001300W WO9205797A1 WO 1992005797 A1 WO1992005797 A1 WO 1992005797A1 JP 9001300 W JP9001300 W JP 9001300W WO 9205797 A1 WO9205797 A1 WO 9205797A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- anticancer
- immunological
- activity
- chemical
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
Definitions
- the present invention is directed to an anticancer drug preparation having both a chemical anticancer effect and an immunological anticancer effect and having a low side effect and a strong antitumor effect.
- anticancer drug preparations used in clinical medicine are roughly classified into chemical anticancer drugs and immunological anticancer drugs.
- the former has a greater anticancer effect than the latter, but has reduced leukopenia.
- the product name is “Roll-A-Trade-Fluid” [Laborato-Meret ⁇ Genorebe's product name]. : HC 0 — 60, Nikko Chemicals, Inc.] and So / Revitanse Schifolate [S 0 — 15, Nikko Chemicals, Inc.] Dissolved, 0.45 m tetrafluoroethylene resin membrane filter [F1 uoropor ⁇ : Nitomo Electric Industries, Ltd.] Use heat to evaporate.
- an aqueous solution of parin 10-stream and an aqueous solution of neocarzinostatin are added, and the mixture is immediately subjected to ultrasonic treatment, and aseptically processed into WZO emulsion.
- other anti-cancer drugs such as adriamycin can be added.
- this anticancer agent When this anticancer agent is injected into a carcinoma, the carcinoma begins to shrink within a few days. This topical chemical effect lasts tens of days as long as the formulation is there. New carcinomas begin to rapidly disintegrate around 3 months after injection .. The injection of the drug is given only once, and this reaction occurs after the local drug has almost disappeared. Thus, the destruction of the carcinoma is an immune response. ⁇ Once a response occurs, it lasts for three years or more as long as the carcinoma is present in the patient.
- the anticancer substance preparation also has an extremely excellent effect in reducing the side effects, which is another object.
- the side effects of this formulation were fever and pain due to mesothelial rupture. This side effect is not due to the formulation itself. Those who do not have cancer, if the size of carcinoma is 5 mm or less, almost no such side effects are seen
- Percutaneous transhepatic neocarcinostatin is a patient who has been treated with this anticancer drug because of severe ascites and severe liver dysfunction due to liver cancer with cirrhosis. Injection of 2 ml of 0 U in 1 containing emulsion into one of the masses. A-fetoprotein, which is a tumor marker of liver cancer, had a dose of 4460 ng and 'm1 before injection, but the carcinoma began to collapse rapidly after 12 weeks.
- Neochemical rutinostatin a chemical anticancer substance alone, does not exert its anticancer effects for more than a few months in a single injection.
- neocarcinostatin which is highly concentrated in the tumor after injection and remains locally in the tumor for a long period of time, exerts a strong chemical anticancer effect and causes tumor necrosis.
- the cell membrane and other cellular components of the necrotic cancer cells are combined with the neo-power / retinostatin 'henolin emulsion, and the bound substance is Makes the patient's immune system recognize the cancer component as a foreign substance. It takes more than about 12 weeks to establish immunity, but just about 12 weeks later, strong destruction of tumor tissue begins. This reaction progresses intensely for several months to several tens of months in proportion to the tumor volume, and tumor destruction proceeds. This immune response persists three years later, as long as the carcinoma is present. Such an intense and long-lasting destruction of cancer is still unknown today.
- This treatment is almost always effective with only one injection. Add several small doses every few days, depending on the size of the tumor and the degree of response.
- the total amount of neocarcinostatin used is 10,000 to 20,000 units. Almost no toxic or side effects seen in bone marrow disorders and other anticancer therapies.
- the immune response of this product is accompanied by leukocytosis. Since the present anticancer drug preparation has an immunological reaction as its main anticancer effect, there are almost no side effects such as those observed with chemical anticancer drugs.
- this emma / resin stably dissolves other chemical anticancer drugs without impairing its effect, if neocarzinostatin cannot be expected to have a chemical action, When it is conceivable, it can be used by additionally dissolving Adriamycin or the like. In addition, since this preparation dissolves protein, it can be used in combination with immunotherapy such as inter-fluorocarbon. Originally, neocarzinostatin is an anticancer drug mainly composed of protein components.
- this anticancer drug formulation is to mix a chemical anticancer drug with a substance that stimulates the immune system and inject it into the tumor, thereby destroying the cancer cells with the anticancer drug and debris of the cancer cells.
- a chemical anticancer drug to phagocytose the macrophages that have migrated by the immunostimulatory substance to enhance the immune recognition of cancer.
- Sulfate polysaccharides disulfate polysaccharides—dextran sulphate, chondroitin sulphate, heparin, etc. as substances that stimulate the immune system.
- Various lipids and natural oils such as linoleic acid and synthetic oils are mixed as lipids such as mysin, etc.
- neocarcinostatin, heparin, rebiodol and interface Emaruji Yo down its physical properties of the active agent was prepared by Ji mixed, the t. this Emma / register Yo down the chemical anti-cancer effect and have you in the immunological anti-cancer action most excellent characteristics were shown rats When injected into the abdominal cavity of the guinea pig, it diffuses and diffuses without dripping for a long time.
- heparin is used as a spacer
- neocarzinostatin, a protein anticancer drug, and lipiodol, an oily substance combine to form a large molecule. Think of it as a thing.
- the chemical / immunological anticancer preparation of the present invention exhibits excellent effects in treating cancer, sarcoma, and the like, and has a chemical / immunological effect on other anticancer agents. It is also used as a base that imparts an anticancer effect.
Abstract
An antineoplastic preparation comprising a mixture of neocarcinostatin (including its derivative), heparin, iodinated poppy seed oil fatty acid ethyl ester, water and surfactant, and having both of chemical and immunological antineoplastic activities. This preparation exhibits a chemical carcinobreaking activity in an early stage of injection and an immunological carcinobreaking activity about 12 weeks thereafter, and the immunological activity is by far potent than the chemical activity. The activity of the preparation lasts over three years as long as the cancer cells survive intact. Since this preparation can readily dissolve various other antineoplastic agents therein, it can impart them an immunological antineoplastic activity.
Description
明 細 書 Specification
化学 · 免疫学的抗癌物質製剤 Chemical and immunological anticancer drugs
[ 技術分野 J [Technical Field J
こ の発明は 、 化学的抗癌作用 と 免疫学的抗癌作用 を合わせ も た副作用の少な い抗腫瘙作用の強い抗癌物質製剤に閲する <. The present invention is directed to an anticancer drug preparation having both a chemical anticancer effect and an immunological anticancer effect and having a low side effect and a strong antitumor effect.
[ 背景技術 ] [Background Technology]
現在、 臨床医学にお いて 用 い られて いる 抗癌物質製剤は 、 化 学的抗癌剤 と 免疫学的抗癌剤に大別さ れる 前者は後者に比ベ て 抗癌効果は大き いが 、 白血球減少 、 貧血 、 脱毛、 口内炎、 肝 At present, anticancer drug preparations used in clinical medicine are roughly classified into chemical anticancer drugs and immunological anticancer drugs.The former has a greater anticancer effect than the latter, but has reduced leukopenia. Anemia, hair loss, stomatitis, liver
P章害、 肺障害 、 さ ら には脳 ， 神経障害等毒作用 、 副作用が強 く こ の系統の薬物を 用いて長期間抗癌効果を持続させる こ と は極 めて困難であ る < 後者は副作用は軽いが、 その抗癌効果は弱く 果た し て抗癌作用があ る のか疑問視される も のす ら あ る .、 ί 発明の開示 ] Chapter P Injury, lung damage, toxic effects such as brain and neuropathy, and side effects are so strong that it is extremely difficult to sustain the anticancer effect for a long time by using this type of drug < Although the latter have slight side effects, their anticancer effects are weak, and it may be questioned whether they have anticancer effects., ΊDisclosure of the Invention]
今 曰 、 臨床に用い られて いる抗癌剤の欠点を克服 し 、 抗癌効 果を高め る 目 的を以て次の よ う な計画の下に抗癌剤の開発研究 を行な つ た -. Now, he has conducted research on the development of anticancer drugs under the following plan with the aim of overcoming the drawbacks of clinically used anticancer drugs and enhancing anticancer effects.
すなはち 、 化学抗癌剤の持つ効力 を 備え 、 他方 、 免疫学的抗 癌剤の持つ効力の持続性 と 皆無に近い無害性を合せ持っ た抗癌 物質製剤の開発研究を行ない 、 毒性の殆 ど無い強力な抗腫瘍作 ffl を持つ持続性の長い抗癌物質製剤を開発する に至っ た <. In other words, the research and development of anticancer substance preparations that possess the efficacy of chemical anticancer drugs, while maintaining the efficacy of immunological anticancer drugs and the almost innocuous properties, have conducted research on almost all toxicity. It has led to the development of a long-lasting anticancer drug with a strong antitumor activity ffl.
( 問題点を解決する ための手段 ） (Means to solve the problem)
リ ヒ才 ド 一 ノレ ゥ ル ト ラ フ ル イ ド [ ラ ボ ラ 卜 ヮ 一 メレ ■ ゲノレベ社 製の商品名 ] にポ リ ォキ シェチ レ ンォキ シ ステ ア リ ン酸 卜 リ グ リ セ ラ イ ド ；： H C 0 — 6 0 , 日光ケ ミ カ ル ズ社製 ] 及びソ /レビ タ ン セ スキォ レエ 一 ト [ S 0 — 1 5 , 日光ケ ミ カル ズ社製 ] を 加え 、 加温溶解 し 、 0 . 4 5 mの 4 弗化工チ レ ン 樹脂製メ ン ブラ ン フ ィ ルタ ー [ F 1 u o r o p o r β ： 注友電気工業社製 ]
を用いて熱時沪過する 。 これにへパリ ン十 ト リ ゥム水溶液、 及 びネオカルチノスタチ ン [科薬社製 ] 水溶液を加え 、 直ちに超 音波処理し、 無菌操作によ り W Z Oェマルジ ヨ ン とする 。 腫瘍 の性質によ ってはこれにア ド リ アマイ シン等他の抗癌剤を追加 する こ とが出来る。 The product name is “Roll-A-Trade-Fluid” [Laborato-Meret ■ Genorebe's product name]. : HC 0 — 60, Nikko Chemicals, Inc.] and So / Revitanse Schifolate [S 0 — 15, Nikko Chemicals, Inc.] Dissolved, 0.45 m tetrafluoroethylene resin membrane filter [F1 uoropor β: Nitomo Electric Industries, Ltd.] Use heat to evaporate. To this, an aqueous solution of parin 10-stream and an aqueous solution of neocarzinostatin (manufactured by Kayaku Co., Ltd.) are added, and the mixture is immediately subjected to ultrasonic treatment, and aseptically processed into WZO emulsion. Depending on the nature of the tumor, other anti-cancer drugs such as adriamycin can be added.
(本抗癌物質製剤の作用〉 (Action of the present anticancer drug formulation)
この抗癌物質製剤を癌腫に注射する と 、 数日中に癌腫が縮小 し始める 。 局所に於ける こ の化学的効果は製剤がそこ にある限 り数十日持続する 。 次いで、 注射後 3 ヶ月前後よ り新たに癌腫 が急速に崩壊し始める ，.. 製剤の注射は最初の 1 回のみで、 しか も局所の薬剤が殆ど消失した後この反応が生 じて く るので、 こ の癌腫の崩壊は免疫反応である <. 一旦生じた反応は患者に癌腫 が存在する限 り 、 3年あるいはそれ以上継続する 。 When this anticancer agent is injected into a carcinoma, the carcinoma begins to shrink within a few days. This topical chemical effect lasts tens of days as long as the formulation is there. New carcinomas begin to rapidly disintegrate around 3 months after injection .. The injection of the drug is given only once, and this reaction occurs after the local drug has almost disappeared. Thus, the destruction of the carcinoma is an immune response. <Once a response occurs, it lasts for three years or more as long as the carcinoma is present in the patient.
本抗癌物質製剤のも う一つの目的である副作用の軽減に於い て も極めて優れた効果を持っている 。 骨髄降害が無く 、 白血球 滅少ゃ貧血が来ない。 む しろ 、 白血球増多が見られる 。 また、 抗癌療法の継続を困難にする 口内炎や皮膚障害が無い。 脱毛も 見られない .、 本製剤の副作用と しては、 瘙腫の破壌に起因する 発熱と疼痛である 。 この副作用は本製剤自 によ る も のではな い。 癌を持たない者、 癌腫の大き さが 5龌以下ではこ の様な副 作用も殆ど見られない The anticancer substance preparation also has an extremely excellent effect in reducing the side effects, which is another object. There is no bone marrow injury, leukocyte depletion or anemia does not come. Rather, leukocytosis is seen. In addition, there are no stomatitis or skin disorders that make it difficult to continue anticancer therapy. No hair loss was observed. The side effects of this formulation were fever and pain due to mesothelial rupture. This side effect is not due to the formulation itself. Those who do not have cancer, if the size of carcinoma is 5 mm or less, almost no such side effects are seen
[実施態様 ] [Embodiment]
次に実施例を挙げて説明する Next, an example will be described.
実施例 1 Example 1
小腸平滑筋肉腫の術後再発例で臍左上部に手拳大の腫瘤あ り これにネオカルチノスタチン 1 0 0 0 U /' m 1 含有エマルジョ ン 5 m 1 を経皮的に注射、 数日後疼痛と と も に腫瘙は膿化し数 日間注射器で吸引。 注射後 4 ヶ月前後よ り再び疼痛を来た し 、 以来、 反応を線り返しながら 4年 2 ヶ月後の今日 、 腫瘤は超音 波上消失し患者は健在である 。 注射は初回 1 回のみである ，
実施例 2 A fist-sized mass in the upper left of the umbilicus in a case of recurrence of small intestine leiomyosarcoma, which was transdermally injected with 5 ml of an emulsion containing neocarzinostatin 100 U / 'm1 After a day of pain, the tumor became purulent and aspirated with a syringe for several days. Pain began again around 4 months after the injection, and since then, the tumor has disappeared on ultrasound and 4 years and 2 months later. Only one injection at the first time, Example 2
肝硬変を伴つ た肝癌で腹水著 し く 肝機能障害が強 いため本抗 癌剤によ る 治療を 行なつ た患者であ る ， 経皮経肝的にネ オカル チ ノ ス タ チ ン 1 0 0 0 U in 1 含有エマル ジ ヨ ン 2 m 1 を腫瘤 の 1 個に注射。 肝癌の腫瘍マ — 力 -- であ る A — フ エ 卜 プロ ティ ン は注射前 4 4 6 0 n g , ' m 1 であ つ たが 1 2 週後よ り 癌腫の 急速な崩壊が始ま り 2 6 6 0 0 II , m 1 に達 し 、 約 3 ヶ 月 間 2 4 2 0 0 n g m 1 の間を上下 し 、 その後は次第に下が り 注 射後 1 0 ヶ月 には 1 3 8 9 0 n g , m 1 に低下 . その後 も 反応 を繰 り返 しながら A — フ ヱ ト プロ テ ィ ン 値は さ ら に低下 、 3 年 後の今日 6 0 0 0 台 と 4 0 0 0 台の間を上下 し ながら 日 常生活 を送って いる 。 C T及び超音波検査上 も癌腫の縮小や消失が証 明される 。 勿論、 注射は最初の 1 回のみであ る Percutaneous transhepatic neocarcinostatin is a patient who has been treated with this anticancer drug because of severe ascites and severe liver dysfunction due to liver cancer with cirrhosis. Injection of 2 ml of 0 U in 1 containing emulsion into one of the masses. A-fetoprotein, which is a tumor marker of liver cancer, had a dose of 4460 ng and 'm1 before injection, but the carcinoma began to collapse rapidly after 12 weeks. It reaches 266,000 II, m 1, rises and falls between 242,000 ngm 1 for about 3 months, and then gradually drops down to 1,380,900 in 10 months after injection ng, m 1, and then the reaction was repeated, and the A-photoprotein value further decreased, between 3 000 today and 4 000 today 3 years later. He lives a daily life while moving up and down. CT and ultrasonography also show that the carcinoma has shrunk or disappeared. Of course, only the first injection
[ 発明の効果 ] [ The invention's effect ]
化学的抗癌物質であ る ネオ力ルチ ノ ス タ チ ン のみでは 1 回の 注射で数ケ月 さ ら には年余にわた っ て抗癌 ί乍用を発揮する こ と は無い。 こ の度開発 した抗癌物質製剤では 、 注射後ネォカルチ ノ ス タ チ ン が腫瘍内に高濃度且つ長期間局所に止ま る ために強 力な化学的抗癌作用 を発揮 し腫瘍は壊死を起こ し臈瘍化する . こ の壊死を起こ し た癌細胞の細胞膜その他の細胞成分 と ネオ力 /レチ ノ ス タ チ ン ' へノ リ ンエマルジ ョ ン が結合 し 、 こ の結合 し た物質がその患者の免疫系にその癌成分を 異種の物質 と して強 く 認識さ せる 。 免疫の成立には約 1 2 週間以上の 日数を必要 と する が丁度その 1 2 週間後頃から腫瘍組織の強い破壊が始る 。 こ の反応は腫瘍量に比例 し て その後数ケ月 〜十数ヶ 月 間激 し く 進行 し 腫瘍の破壊が進む。 こ の免疫反応は癌腫が存在す る 限 り 三年後で も続 く 。 こ の様な強烈に且つ長期間にわた っ て癌破壊 を継続する 癌免疫反応は今日未だ知られて いない。 Neochemical rutinostatin, a chemical anticancer substance alone, does not exert its anticancer effects for more than a few months in a single injection. With the newly developed anticancer drug, neocarcinostatin, which is highly concentrated in the tumor after injection and remains locally in the tumor for a long period of time, exerts a strong chemical anticancer effect and causes tumor necrosis. The cell membrane and other cellular components of the necrotic cancer cells are combined with the neo-power / retinostatin 'henolin emulsion, and the bound substance is Makes the patient's immune system recognize the cancer component as a foreign substance. It takes more than about 12 weeks to establish immunity, but just about 12 weeks later, strong destruction of tumor tissue begins. This reaction progresses intensely for several months to several tens of months in proportion to the tumor volume, and tumor destruction proceeds. This immune response persists three years later, as long as the carcinoma is present. Such an intense and long-lasting destruction of cancer is still unknown today.
こ の治療は殆ど初回 1 回のみの注射で効果を現す .. 腫瘍の大 き さや反応の程度に よ っ て は数 日毎に少量ずつ数回追加する 。 使用する ネオカルチ ノ ス タ チンの量は総計 1 万乃至 2 万単位で
あ り 骨髄障害その他抗癌療法に見 られる毒作用 、 副作用は殆ど 全 く 見られない。 本製剤の免疫反応は白血球増多を伴 う も ので あ る 。 本抗癌物質製剤は免疫反応を その抗癌作用の主体と して いる ので、 化学的抗癌剤に見られる よ う な副作用は全く と 言つ て いいほ ど見られない .， This treatment is almost always effective with only one injection. Add several small doses every few days, depending on the size of the tumor and the degree of response. The total amount of neocarcinostatin used is 10,000 to 20,000 units. Almost no toxic or side effects seen in bone marrow disorders and other anticancer therapies. The immune response of this product is accompanied by leukocytosis. Since the present anticancer drug preparation has an immunological reaction as its main anticancer effect, there are almost no side effects such as those observed with chemical anticancer drugs.
ま た 、 こ のエマ /レジ ョ ンは他の化学的抗癌剤を その効果を損 な う こ と な く 安定的に溶解させる ので、 も し ネオカ ルチノ ス タ チンでは化学的作用が期待でき ない と 考え られる 時は 、 これに ア ド リ アマイ シ ン等を追加溶解 し て使用出来る 。 ま た 、 本製剤 は蛋白 を溶存せ しめ う る ので、 イ ンタ — フ c ロ ン等の免疫療法 剤を混 じて 使用する こ と が出来る 。 も と も と ネオカルチ ノ ス タ チンが蛋白成分を主体と する抗癌剤であ る 。 In addition, since this emma / resin stably dissolves other chemical anticancer drugs without impairing its effect, if neocarzinostatin cannot be expected to have a chemical action, When it is conceivable, it can be used by additionally dissolving Adriamycin or the like. In addition, since this preparation dissolves protein, it can be used in combination with immunotherapy such as inter-fluorocarbon. Originally, neocarzinostatin is an anticancer drug mainly composed of protein components.
本抗癌物質製剤の開発思想は、 免疫系を刺激する物質に化学 抗癌剤を混 じ 、 これを腫瘙内に注入する こ と によ り 抗癌剤で癌 細胞を破壊 し 、 癌細胞の破細片を免疫剌激物質によ っ て遊走 し て き たマク ロ フ ァ ー ジに貪食させ癌に対する 免疫的認識を高め よ う と い う こ と にあ る 。 免疫系を刺激する物質と して 、 硫酸多 糖類—硫酸デキ ス ト ラ ン 、 硫酸コ ン ド ロ イ チ ン 、 へパ リ ン等一 化学抗癌剤 と し て ア ド リ アマイ シ ン 、 マイ ト マイ シ ン等、 脂質 と し て リ ノ ール酸等の天然油脂及び合成油、 それぞれを種 々混 合 · 実験の結果、 ネオカルチノス タ チ ン 、 へパ リ ン 、 リ ビオ ド ー ル及び界面活性剤を混 じて 作製 したェマルジ ヨ ンがその物性 、 化学的抗癌作用及び免疫学的抗癌作用にお いて最も優れた特 性を示 した t. こ のエマ /レジ ヨ ンを ラ ッ ト の腹腔内に注射する と 、 長期間滴状化する こ と 無く 瀰漫性に拡散 して存在する 。 こ の ェマルジ ョ ンはへパ リ ンをスぺ一サ一 と して蛋白抗癌剤であ る ネオカルチノ ス タ チン と油質であ る リ ピオ ド ー ルが結合 し大き な分子を形成 して いる 物と考え る 。 これに抗癌作用によ っ て破 壊された癌細胞の成分が結合 して 巨大分子を形成、 こ の巨大分 子を マク ロ フ ァ -- ジが貪食 し免疫的抗癌作用のス タ - ト が切ら れる 。 油質と し て リ ビオ ド ールを採用 したのは動物実験で リ ノ ール酸等に比べて毒作用が殆ど無かっ た こ と 、 長年月 に直っ て
臨床で使用 され毒性等 も既に充分理解され安全性が高いこ と 、 さ ら に 、 造影剤であ る ので薬剤の注射部位が確認出来る こ と 等 によ る <. The idea behind the development of this anticancer drug formulation is to mix a chemical anticancer drug with a substance that stimulates the immune system and inject it into the tumor, thereby destroying the cancer cells with the anticancer drug and debris of the cancer cells. To phagocytose the macrophages that have migrated by the immunostimulatory substance to enhance the immune recognition of cancer. Sulfate polysaccharides—dextran sulphate, chondroitin sulphate, heparin, etc. as substances that stimulate the immune system. Various lipids and natural oils such as linoleic acid and synthetic oils are mixed as lipids such as mysin, etc. ・ As a result of experiments, neocarcinostatin, heparin, rebiodol and interface Emaruji Yo down its physical properties of the active agent was prepared by Ji mixed, the t. this Emma / register Yo down the chemical anti-cancer effect and have you in the immunological anti-cancer action most excellent characteristics were shown rats When injected into the abdominal cavity of the guinea pig, it diffuses and diffuses without dripping for a long time. In this emulsion, heparin is used as a spacer, and neocarzinostatin, a protein anticancer drug, and lipiodol, an oily substance, combine to form a large molecule. Think of it as a thing. The components of the cancer cells destroyed by the anticancer action combine with this to form macromolecules, and macrophages phagocytose these macromolecules, leading to immunological anticancer actions. -You are cut off. The use of Liviodol as an oil was based on the fact that it had almost no toxic effects compared to linoleic acid in animal tests. Because it is used in clinical practice and its toxicity is well understood and its safety is high, and since it is a contrast agent, the injection site of the drug can be confirmed.
[ 産業上の利用可能性 ] [Industrial applicability]
以上のよ う に 、 本発明にかかる化学 ' 免疫学的抗癌物質製剤 は 、 それ 自体 、 癌や肉腫等の治療に優れた効果を 発揮する と と も に 、 他の抗癌剤に化学 · 免疫学的抗癌作用 を付与する基剤と し て も 用い られる ，
As described above, the chemical / immunological anticancer preparation of the present invention exhibits excellent effects in treating cancer, sarcoma, and the like, and has a chemical / immunological effect on other anticancer agents. It is also used as a base that imparts an anticancer effect.
Claims
請 求 の 範 囲 The scope of the claims
. ネオカルチノスタチン （誘導体を含む〉 、 へパリ ン 、 ョ — ド化ケシ油脂肪酸ェチルエステル、 水及び界面活性剤よ り得 られる化学的抗癌作用と免疫学的抗癌作用を併せ持つこ と を 特徴とする抗癌物質製剤。 Neocarzinostatin (including derivatives), heparin, phosphatized poppy oil fatty acid ethyl ester, water and surfactants have a combined chemical and immunological anticancer effect. Characteristic anticancer substance preparation.
. 他の抗癌物質に化学的並びに免疫学的抗癌作用を付与する 機能を有する こ と を特徴とする請求の範囲第 1 項記載の抗癌 物質製剤。
2. The anticancer substance preparation according to claim 1, having a function of imparting a chemical and immunological anticancer action to another anticancer substance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP1990/001300 WO1992005797A1 (en) | 1990-10-05 | 1990-10-05 | Chemico-inmunological antineoplastic preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP1990/001300 WO1992005797A1 (en) | 1990-10-05 | 1990-10-05 | Chemico-inmunological antineoplastic preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1992005797A1 true WO1992005797A1 (en) | 1992-04-16 |
Family
ID=13986766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1990/001300 WO1992005797A1 (en) | 1990-10-05 | 1990-10-05 | Chemico-inmunological antineoplastic preparation |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1992005797A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0585058A1 (en) * | 1992-08-25 | 1994-03-02 | Scotia Holdings Plc | Pharmaceutical compositions containing fatty acids and heparin |
| US5954737A (en) * | 1997-12-19 | 1999-09-21 | Neurovasx, Inc. | Thrombus macerator catheter |
| CN107287029A (en) * | 2016-05-30 | 2017-10-24 | 江苏恒瑞医药股份有限公司 | A kind of preparation method of iodized vegetable fatty acids ethyl ester |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4888220A (en) * | 1972-03-04 | 1973-11-19 | ||
| JPS52139789A (en) * | 1976-05-14 | 1977-11-21 | Microbial Chem Res Found | Method of preparing stable powder of neocarzinostatin |
| JPS6485922A (en) * | 1986-09-19 | 1989-03-30 | Yamanouchi Pharma Co Ltd | Neocarzinostatin derivative composition for noninjection administration |
-
1990
- 1990-10-05 WO PCT/JP1990/001300 patent/WO1992005797A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4888220A (en) * | 1972-03-04 | 1973-11-19 | ||
| JPS52139789A (en) * | 1976-05-14 | 1977-11-21 | Microbial Chem Res Found | Method of preparing stable powder of neocarzinostatin |
| JPS6485922A (en) * | 1986-09-19 | 1989-03-30 | Yamanouchi Pharma Co Ltd | Neocarzinostatin derivative composition for noninjection administration |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0585058A1 (en) * | 1992-08-25 | 1994-03-02 | Scotia Holdings Plc | Pharmaceutical compositions containing fatty acids and heparin |
| US5954737A (en) * | 1997-12-19 | 1999-09-21 | Neurovasx, Inc. | Thrombus macerator catheter |
| CN107287029A (en) * | 2016-05-30 | 2017-10-24 | 江苏恒瑞医药股份有限公司 | A kind of preparation method of iodized vegetable fatty acids ethyl ester |
| CN107287029B (en) * | 2016-05-30 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | Preparation method of iodized vegetable oil fatty acid ethyl ester |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3966908A (en) | Method of treating degenerative joint afflictions | |
| CN116808219A (en) | Gamma secretase modulators for the treatment of immune system dysfunction | |
| JPH0629196B2 (en) | Physiological action enhancer for tumor treatment by ultrasound | |
| Mayer et al. | Complications of irradiation related to apparent drug potentiation by adriamycin | |
| TW201242606A (en) | Hemostatic preparation containing an extract of golden moss | |
| RU2593848C2 (en) | Anticancer drug containing carbon dioxide as an active ingredient | |
| WO1992005797A1 (en) | Chemico-inmunological antineoplastic preparation | |
| CN109820824B (en) | Capsaicin liquid crystal nano spray preparation for promoting skin wound healing and preparation method thereof | |
| US3548052A (en) | Heparin compositions and methods of using same | |
| Boudreaux et al. | Bioassay of a hemostatic factor from peanuts | |
| JP2003277281A (en) | Medicine for preventing and curing phlebitis | |
| JPH0543687B2 (en) | ||
| Jeglum et al. | Intralymphatic autochthonous tumor cell vaccine in canine lymphoma | |
| Carr et al. | Lymphatic metastasis; lymphangiochemotherapy of mammary cancer: ascitic form of rat mammary adenocarcinoma 13762 | |
| JPS5839619A (en) | Medicinal composition and manufacture | |
| EA200100223A3 (en) | Water dispersed ivermectin dosage form for curing ecto- endoparasitic diseases | |
| Javadpour et al. | Bladder toxicity due to cyclophosphamide: Experimental induction and treatment | |
| JPS6053150A (en) | Rubbery sticky bandage | |
| MXPA01001490A (en) | Transdermally delivered aspirin. | |
| JP2007314450A (en) | Cataplasm for easing pollinosis | |
| Aminkov et al. | Electrochemotherapy--a novel method of treatment of malignant tumors in dog | |
| CN100333715C (en) | Magnetic medicinal microball for directional breaking nerve back root and its preparing method | |
| Goldman et al. | Clinical and histologic evaluation of polyiodinated iodine with and without hypertonic saline/dextrose in the rabbit ear vein model | |
| US1579086A (en) | Medicinal composition | |
| Sumi et al. | Investigation of the Different Ethnopharmacological Activity of Fractional Root Extracts of Mussaenda roxburghii in in vitro Model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR CA FI HU JP KR LK MC MG MW NO RO SD SU US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |